Tabrecta (capmatinib) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tabrecta is used in ...

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their ...

Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta ...

Tabrecta approved in Europe Meanwhile, Novartis also has good news in its targeted oncology business on the other side of the Atlantic, as the European Commission has approved its Incyte-partnered ...

In the US, it is competing in the METex14-positive NSCLC market with Novartis/Incyte's rival MET inhibitor Tabrecta (capmatinib). The EAMS opinion is based on results from the phase 2 VISION study ...